期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

EGFR／HER-2双受体酪氨酸激酶抑制剂拉帕替尼的研究进展 被引量：6

Progress of study on lapatinib
下载PDF
导出
摘要 EGFR/HER-2是理想的抗肿瘤分子靶点。拉帕替尼(lapatinib)是口服的小分子EGFR/HER-2双受体酪氨酸激酶抑制剂,体内外的临床前试验证实了lapatinib的抗肿瘤活性,Ⅰ期临床研究显示了它的安全性,治疗侵袭、复发、炎性、脑转移乳癌的Ⅱ、Ⅲ期临床研究取得了可喜的成绩。随着对乳癌生物特性的理解,选择特异的肿瘤亚型(HER-2过表达),进行分子靶向治疗(例如lapatinib)正成为一种新的辅助治疗方案。 EGFR/HER-2 is an attractive therapeutic target for solid tumors. Lapatinib is an orally administered dual inhibitor of EGFR/HER-2 tyosine kinases. Preclinical experiments in vitro and in vivo models indicate that lapatinib is active against various solid tumors. Phase Ⅰ trials have shown an acceptable adverse event. Phase Ⅱ and Ⅲ trials demonstrate the promising results for the treatment of metastatic, refractory, inflammatory, or brain metastatic breast cancer. With the further developments of biology, the molecular targeted chemotherapy becomes a novel adjuvant therapy for advanced breast cancer patients.
作者 陶黎阳 符立梧
机构地区 华南肿瘤学国家重点实验室中山大学肿瘤防治中心
出处 《中国药理学通报》 CAS CSCD 北大核心 2008年第12期1541-1544,共4页 Chinese Pharmacological Bulletin
关键词 LAPATINIB 上皮生长因子受体家族 乳腺癌 lapatinib ErbB family breast cancer
分类号 R-05 [医药卫生] R392.1 [医药卫生—免疫学]
  • 相关文献

参考文献38

  • 1Olayioye M A, Neve R M, Lane H A, et al. The ErbB signaling net work : receptor heterodimerization in development and cancer [ J ]. EMBO J,2000 ,19(13 ) :3159 -67.
  • 2Roskoski R Jr. The ErbB/HER receptor protein tyrosine kinases and cancer[ J]. Biochem Biophys Res Commun ,2004,319( 1 ) : 1 - 11.
  • 3Moy B, Goss P E. Lapatinib current status and future directions in breast cancer[ J ]. The Oncologist,2006,11 ( 10 ) : 1047 - 57.
  • 4Dillon R L, Write D E, Muller W J, et al. The phosphatidylinositol3-kinase signaling network:implications for human breast cancer [ J]. Oncogerte ,2007 ,26 (9) : 1338 - 45.
  • 5Rusnak D W, Lackey K, Affleck K, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumorderived cell lines in vitro and in vivo [ J ]. Mol Cancer Ther,2001,1 (1) :85 -94.
  • 6Xia W, Mullin R J, Keith B R, et al. Anti-tumor activity of GW572016 ,a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and Akt path ways[ J]. Oncogene, 2002,21 ( 41 ) : 6255 - 63.
  • 7Spector N L, Xia W, Burris H, et al. Study of the biologic effects of lapatinib,a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases,on tumor growth and survival pathways in patients with advanced malignancies[ J]. J Clin Oncol,2005,23 ( 11 ) :2502 - 12.
  • 8Nelson M H, Dolder C R. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors [ J ]. Ann Pharmacother, 2006,40(2) :261 -9.
  • 9Kim T E, Murren J R, Lapatinib ditosylate GlaxoSmithKline [ J ]. IDrugs,2003,6(9) :886 -93.
  • 10Moy B,Kirkpatrick P,Kar S,Goss P. Lapatinib[J]. Nat Rev Drug Discov,2007,6(6) :431 -2.

同被引文献68

  • 1Yun Dai , Wei-Hong Wang.Peroxisome proliferator-activated receptor γ and colorectal cancer[J].World Journal of Gastrointestinal Oncology,2010,2(3):159-164. 被引量：5
  • 2陆应麟.上皮生长因子受体在肿瘤转移中的作用研究进展[J].解放军医学情报,1994,8(6):311-312. 被引量：1
  • 3Takashi Fujimura,Tetsuo Ohta,Katsunobu Oyama,Tomoharu Miyashita,Koichi Miwa.Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: A review and report of personal experience[J].World Journal of Gastroenterology,2006,12(9):1336-1345. 被引量：33
  • 4谢富华,王润秀,梁念慈.表皮生长因子受体家族信号转导途径与乳腺癌关系的研究进展[J].国际检验医学杂志,2006,27(11):1004-1005. 被引量：2
  • 5Konecny GE, Pegram MD, Venkatesan N, et al. Activityof the dual kinase inhibitor lapatinib(GW572016) againstHER-2-overexpressing and trastuzumab-treated breastcancer cells[J]. Cancer Res,2006 ,66(3) : 1630-1639.
  • 6Xia W’Mullin RJ,Keith BR, et al. Anti-tumor activity ofGW572016 : a dual tyrosine kinase inhibitor blocks EOFactivation of E8GFR/erbB2 and downstream Erkl/2 andAKT pathways[J]. Oncogene,2002 ,21(41) : 6225-6263.
  • 7Evans AH, Pancholi S, Farmer I, et al. EGFR/HER2 in-hibitor AEE788 increases ER-mediated transcription inHER2/ER-positive breast cancer cells but functions syn-ergistically with endocrine therapy[J]. Br J Cancer,2010,102(8):1235-1243.
  • 8Xia W, Liu LH, Ho P? et al. Truncated ErbB2 receptor(p95 ErbB2 ) is regulated by heregulin through het-erodimer formation with ErbB3 yet remains sensitive tothe dual EGFR/ErbB2 kinase inhibitor GW572016 [J].Oncogene,2004,23(3):646-653.
  • 9Ciardiello F,Caputo R? Bianco R,et al. Antitumor effectand potentiation of cytotoxic drugs activity in humancancer cells by ZD1839(Iressa) ?an epidermal growth fac-tor receptor-selective tyrosine kinase inhibitor [J ]. ClinCancer Res?2000,6 ; 2053-2063.
  • 10Rusnak DW,Lackey K,Affleck K,et al. The effects of thenovel,reversible epidermal growth factor receptor/ErbB-2tyrosine kinase inhibitor,GW572016,on the growth ofhuman normal and tumor-derived cell lines in vitro and invivo[J], Mol Cancer Ther,2001,1(2) :85-94.

引证文献6

二级引证文献17

中国药理学通报
2008年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部